PL399137A1 - Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego - Google Patents

Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Info

Publication number
PL399137A1
PL399137A1 PL399137A PL39913701A PL399137A1 PL 399137 A1 PL399137 A1 PL 399137A1 PL 399137 A PL399137 A PL 399137A PL 39913701 A PL39913701 A PL 39913701A PL 399137 A1 PL399137 A1 PL 399137A1
Authority
PL
Poland
Prior art keywords
peptide
pharmaceutical composition
tolerogenic
administration
application
Prior art date
Application number
PL399137A
Other languages
English (en)
Other versions
PL215187B1 (pl
Inventor
Stephen Mark Anderton
Graziella Mazza
Mary Ponsford
Heather Barbara Streeter
David Cameron Wraith
Original Assignee
Apitope Technology (Bristol) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL399137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0020618A external-priority patent/GB0020618D0/en
Priority claimed from GB0114547A external-priority patent/GB0114547D0/en
Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited
Publication of PL399137A1 publication Critical patent/PL399137A1/pl
Publication of PL215187B1 publication Critical patent/PL215187B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
PL399137A 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego PL215187B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0020618A GB0020618D0 (en) 2000-08-21 2000-08-21 Peptide selection method
GB0114547A GB0114547D0 (en) 2001-06-14 2001-06-14 Peptide selection method

Publications (2)

Publication Number Publication Date
PL399137A1 true PL399137A1 (pl) 2012-07-30
PL215187B1 PL215187B1 (pl) 2013-11-29

Family

ID=26244875

Family Applications (4)

Application Number Title Priority Date Filing Date
PL399137A PL215187B1 (pl) 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL395781A PL213585B1 (pl) 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL364048A PL217929B1 (pl) 2000-08-21 2001-08-17 Sposób wyboru in vitro peptydu przydatnego w zapobieganiu i/lub leczeniu chorób z nadmiernym uczuleniem
PL399138A PL215145B1 (pl) 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL395781A PL213585B1 (pl) 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL364048A PL217929B1 (pl) 2000-08-21 2001-08-17 Sposób wyboru in vitro peptydu przydatnego w zapobieganiu i/lub leczeniu chorób z nadmiernym uczuleniem
PL399138A PL215145B1 (pl) 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Country Status (25)

Country Link
US (4) US20030191063A1 (pl)
EP (3) EP1311542B1 (pl)
JP (1) JP5431628B2 (pl)
KR (1) KR20030062321A (pl)
CN (4) CN102764425B (pl)
AT (2) ATE483729T1 (pl)
AU (2) AU2001278637B2 (pl)
BR (2) BRPI0113400B1 (pl)
CA (1) CA2420949C (pl)
CY (3) CY1108558T1 (pl)
CZ (1) CZ307202B6 (pl)
DE (2) DE60143234D1 (pl)
DK (3) DK1311542T3 (pl)
ES (3) ES2310558T3 (pl)
HK (3) HK1052359B (pl)
HU (3) HU229377B1 (pl)
IL (1) IL154089A0 (pl)
MX (1) MXPA03001606A (pl)
NO (2) NO330535B1 (pl)
NZ (1) NZ523841A (pl)
PH (1) PH12013500208B1 (pl)
PL (4) PL215187B1 (pl)
PT (3) PT1918298E (pl)
SI (3) SI1731912T1 (pl)
WO (1) WO2002016410A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
EP2420833B1 (en) * 2006-05-05 2015-09-02 Opexa Therapeutics T-cell vaccine
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CN101820907B (zh) 2007-08-15 2013-05-01 切尔卡西亚有限公司 针对过敏原去敏化的肽
DK2211892T3 (da) * 2007-10-31 2011-10-31 Apitope Technology Bristol Ltd Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
ITMI20080508A1 (it) * 2008-03-27 2009-09-28 Istituto Nazionale Di Genetica Molecolare Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CN102781465A (zh) 2009-10-12 2012-11-14 生命生物实验室有限公司 用于治疗多发性硬化的组合物
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
PT2556171E (pt) 2010-04-05 2015-12-21 Prognosys Biosciences Inc Ensaios biológicos codificados espacialmente
KR200457779Y1 (ko) * 2010-06-23 2012-01-06 이준혁 샤프펜슬
US20120258871A1 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
PL397623A1 (pl) * 2011-12-30 2013-07-08 Napco S. Ar.L. Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
CN104903347B (zh) 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN111233978A (zh) 2013-03-15 2020-06-05 普罗格诺西斯生物科学公司 用于检测肽/mhc/tcr结合的方法
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2016103213A1 (en) * 2014-12-24 2016-06-30 Apitope International Nv Composition
CN113186256A (zh) 2015-04-10 2021-07-30 空间转录公司 生物样本的空间区别、多重核酸分析
JP2020503353A (ja) * 2017-01-04 2020-01-30 アピトープ インターナショナル エヌブイ 寛容原性ペプチドを用いた治療方法
EP3565823A1 (en) 2017-01-04 2019-11-13 Apitope International NV S-arrestin peptides and therapeutic uses thereof
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
RU2725811C1 (ru) 2017-01-06 2020-07-06 Ютайлекс Ко., Лтд. Антитела против 4-1bb человека и их применение
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
RU2761617C2 (ru) * 2019-10-04 2021-12-13 Жаудат Гафурович Умеров Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
GB201919222D0 (en) 2019-12-23 2020-02-05 Apitope Int Nv Composition
TR201922305A2 (tr) * 2019-12-30 2021-07-26 T C Erciyes Ueniversitesi Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US20230172894A1 (en) 2020-05-06 2023-06-08 Imcyse Sa Combination treatment for fumarate-related diseases
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327162C (en) 1987-04-09 1994-02-22 Board Of Trustees Of The Leland Stanford Junior University (The) Method for prophylactically treating an individual for an autoimmune disease
ATE258065T1 (de) 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
CA2189990A1 (en) * 1994-05-10 1995-11-16 Di-Hwei Hsu Compositions and treatment for multiple sclerosis
AU7242994A (en) 1994-05-20 1995-12-18 United States Of America, As Represented By The Secretary Of The Army, The Model for testing immunogenicity of peptides
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996032957A1 (en) * 1995-04-20 1996-10-24 Brigham & Women's Hospital Modulation of cytokine patterns of human autoreactive t-cell clones
DE69723434T2 (de) * 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
EP0849275A1 (en) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
WO1999063945A2 (en) 1998-06-12 1999-12-16 Sloan-Kettering Institute For Cancer Research Vaccination strategy to prevent and treat cancers
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
HU229377B1 (hu) 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US8314290B2 (en) 2004-12-21 2012-11-20 Monsanto Technology Llc Temporal regulation of gene expression by MicroRNAs
DK2211892T3 (da) * 2007-10-31 2011-10-31 Apitope Technology Bristol Ltd Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides

Also Published As

Publication number Publication date
NO337988B1 (no) 2016-07-18
EP1311542B1 (en) 2008-07-16
PT1918298E (pt) 2010-12-09
EP1731912A2 (en) 2006-12-13
CY1111079T1 (el) 2015-06-11
CN101633689B (zh) 2013-09-04
EP1918298B1 (en) 2010-10-06
HK1178437A1 (en) 2013-09-13
CY1108558T1 (el) 2014-04-09
CN102764425B (zh) 2015-11-25
ES2439899T3 (es) 2014-01-27
HUP0300814A2 (hu) 2003-10-28
US20130156798A1 (en) 2013-06-20
CN1469883A (zh) 2004-01-21
NO330535B1 (no) 2011-05-09
AU2001278637B2 (en) 2006-05-25
CY1114808T1 (el) 2016-12-14
HUP0300814A3 (en) 2005-11-28
SI1731912T1 (sl) 2014-05-30
JP5431628B2 (ja) 2014-03-05
ES2353347T3 (es) 2011-03-01
PH12013500208A1 (en) 2015-04-20
EP1918298A2 (en) 2008-05-07
CA2420949C (en) 2012-01-03
NO20030790L (no) 2003-04-22
SI1311542T1 (sl) 2009-02-28
KR20030062321A (ko) 2003-07-23
PL215145B1 (pl) 2013-10-31
US8343500B2 (en) 2013-01-01
NO20030790D0 (no) 2003-02-19
PH12013500208B1 (en) 2015-04-20
BR0113400A (pt) 2003-07-08
ES2310558T3 (es) 2009-01-16
DE60134862D1 (de) 2008-08-28
HU229489B1 (hu) 2014-01-28
CN101633689A (zh) 2010-01-27
DK1311542T3 (da) 2008-11-10
HK1052359A1 (en) 2003-09-11
WO2002016410A3 (en) 2002-09-12
PL213585B1 (pl) 2013-03-29
EP1311542A2 (en) 2003-05-21
DE60143234D1 (de) 2010-11-18
HU230233B1 (hu) 2015-10-28
NO20101441L (no) 2003-04-22
SI1918298T1 (sl) 2011-01-31
EP1731912B1 (en) 2013-09-25
EP1918298A3 (en) 2008-05-28
HU229377B1 (hu) 2013-11-28
CZ307202B6 (cs) 2018-03-21
HK1178793A1 (en) 2013-09-19
MXPA03001606A (es) 2004-11-01
EP1731912A3 (en) 2006-12-27
CA2420949A1 (en) 2002-02-28
IL154089A0 (en) 2003-07-31
ATE401343T1 (de) 2008-08-15
PL399138A1 (pl) 2012-07-30
PL364048A1 (pl) 2004-12-13
NZ523841A (en) 2004-07-30
WO2002016410A2 (en) 2002-02-28
US20180311328A1 (en) 2018-11-01
ATE483729T1 (de) 2010-10-15
CN102784385A (zh) 2012-11-21
PT1731912E (pt) 2013-12-17
DK1918298T3 (da) 2010-11-29
BRPI0113400B1 (pt) 2018-05-15
AU7863701A (en) 2002-03-04
CN102764425A (zh) 2012-11-07
US20080200368A1 (en) 2008-08-21
HK1052359B (zh) 2008-11-14
US8961986B2 (en) 2015-02-24
PL215187B1 (pl) 2013-11-29
PT1311542E (pt) 2008-10-03
US20030191063A1 (en) 2003-10-09
DK1731912T3 (da) 2014-01-06
CN102784385B (zh) 2015-11-25
JP2004506921A (ja) 2004-03-04
PL217929B1 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
PL399137A1 (pl) Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
AU2002229510A1 (en) Combined use of factor vii polypeptides and factor viii polypeptides
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
HUP0401121A2 (hu) Csökkentett immunogenitású, módosított trombopoietin (TPO)
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben